Journey Medical Corp. DERM 深 沪
已收盘 02-06 16:00:00 美东时间
8.35
0.000
0.00%
华盛通- 最 高8.5323
- 今 开8.49
- 成交量 5.51万股
- 最 低 8.33
- 昨 收 8.35
- 总市值 2.78亿
- 52周最高 9.555
- 市盈率 静 --
- 换手率 0.17%
- 52周最低 4.85
- 委 比 -39.78%
- 总股本 3325.66万
- 历史最高 10.20
- 量 比 0.75
- 振 幅 2.42%
- 历史最低 1.02
- 每 手 1
- 风险率 0.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Journey Medical Files $3.75M At-The-Market Common Stock Offering With B. Riley And Lake Street
3,750,000 SHARES OF COMMON STOCKWe have entered into an At Market Issuance Sales Agreement (the "Sales Agreement") with B. Riley Securities, Inc. ("B. Riley") and Lake Street Capital Markets, LLC ("Lake Street") (each,
01-24 05:13
Journey Medical Q3 EPS $(0.09) Misses $(0.04) Estimate, Sales $17.631M Miss $18.854M Estimate
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.04) by 143.24 percent. This is a 25 percent increase over losses of $(0.12) per share from
2025-11-13 05:02
Insights into Journey Medical's Upcoming Earnings
Journey Medical (NASDAQ:DERM) will release its quarterly earnings report on Wed...
2025-11-12 02:03
Journey Medical Corporation Releases Pooled Phase 3 Data From Its MVOR-1 And MVOR-2 Trials Evaluating DFD-29 Demonstrating Emrosi's Statistical Superiority Over Oracea And Placebo In Achieving Investigator's Global Assessment Treatment Success And Reducing Inflammatory Lesion Counts
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea
2025-10-24 20:33
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
FDA-approved Emrosi (DFD-29), a modified-release minocycline formulation, has demonstrated superior efficacy in treating inflammatory lesions of rosacea in adults compared to both placebo and doxycycline in two Phase 3 clinical trials. Emrosi achieved statistically significant higher Investigator’s Global Assessment (IGA) success rates (62.7%) and greater reductions in inflammatory lesion counts (-19.2) compared to Oracea (39.0%, -14.8) and place...
2025-10-24 12:30
Journey Medical Corporation to Participate in September 2025 Investor Conferences
Journey Medical Corporation’s CEO Claude Maraoui to attend two September 2025 investor conferences in New York City. The events include H.C. Wainwright’s Global Investment Conference on Sept 8 and Lake Street Capital’s BIG9 Conference on Sept 11. Both are in NYC with fireside chat and 1x1 meetings format. The company focuses on marketing FDA-approved dermatological products and currently markets eight branded prescription drugs.
2025-09-03 12:30
Journey Medical Corp Enters New Sales Agreement
The latest announcement is out from Journey Medical Corp ( ($DERM) ). On August...
2025-08-29 05:53
HC Wainwright & Co. Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $13
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $13.
2025-08-25 19:35
Journey Medical Corporation to Present at the Emerging Growth Conference
Journey Medical Corporation (NASDAQ: DERM) announced that its CEO, Claude Maraoui, will present a corporate overview at the Emerging Growth Conference on August 20, 2025, at 12:35 p.m. ET via a virtual video webcast. For more details or to register, visit EmergingGrowth.com. An archived webcast will be available later. Journey Medical specializes in marketing FDA-approved prescription drugs for dermatological conditions and currently offers eight...
2025-08-18 12:30
